glp 1 and diabetes GLP-1-based therapies for type 2 diabetes: from single, dual triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 receptor agonists | How

Updated September 8, 2023

One of the most promising treatments we offer is Semaglutide GLP-1, a glucagon-like peptide-1 (GLP-1) receptor agonist that has shown exceptional effectiveness in facilitating weight loss for overweight or obese adults

Its website states that compounded versions are not FDA-approved, which is a disclosure many clinics either bury or omit entirely

Mood improvement often follows initial adjustment periods, particularly as weight loss progresses and metabolic health improves

Clinical evidence suggests that without the medication, maintaining weight loss can be extremely difficult, highlighting the necessity of a well-thought-out ramp down strategy to avoid gaining back the weight thats been lost